TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29598955
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain during chemotherapy (≥ 5% increase)
Study: 29598955
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss during chemotherapy (≥ 5% decrease)
Study: 29598955
Drug: Stable weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable weight during chemotherapy
Study: 15921758
Drug: 0.59‐mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.59‐mg fluocinolone acetonide intravitreal implant
Study: 15921758
Drug: 2.1‐mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.1‐mg fluocinolone acetonide intravitreal implant
Study: 12358873
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (n = 29) with conjugated equine oestrogen (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day)
Study: 10415739
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose of doxycycline (SDD)
Study: 2105538
Drug: Eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic acid (EPA) 100 mg daily for 2 months
Study: 473929
Drug: Intraarticular administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular administration of 125 mg/0.5 ml Arteparon (6 injections)
Study: 473929
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 125 mg/0.5 ml Arteparon (10 injections)
Study: 473929
Drug: Intraarticular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular and Intramuscular administration of Arteparon
Study: 24521993
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (1400 mg)
Study: 19512978
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg/d
Study: 8511923
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with PMUE therapy: cisplatin (CDDP) 75 mg/m2, mitomycin C (MMC) 10 mg/body, etoposide 150 mg/body, and UFT 400 mg/day.
Study: 8511923
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (surgery first, then PMUE therapy).
Study: 8511923
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) group.
Study: 30402206
Drug: High vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vegetable consumption (4200 g of vegetables/week)
Study: 30402206
Drug: Low vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low vegetable consumption (800 g of vegetables/week)
Study: 22875224
Drug: Vacuum‐assisted closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum‐assisted closure (VAC) therapy
Study: 15883427
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary zinc intake (3.8 mg/d)
Study: 15883427
Drug: Supplemented zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemented zinc intake (18.7 mg/d)
Study: 12452732
Drug: Liposomal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal formulation of anthracyclines
Study: 12452732
Drug: Cardioprotective agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioprotective agents
Study: 12452732
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of anthracyclines
Study: 12452732
Drug: Timed sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed sequential therapy
Study: 7740949
Drug: Parenteral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cefuroxime
Study: 7069203
Drug: UVA treatment
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA treatment
Study: 7069203
Drug: 8‐methoxypsoralen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐methoxypsoralen treatment
Study: 22536131
Drug: Interferon-gamma (IFN-γ)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (IFN-γ) 50 μg/m² subcutaneously three times per week (n = 20)
Study: 22536131
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone valerate 0.1% cream every night for 30 days (n = 20)
Study: 19696126
Drug: Self-administered computerized
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered computerized versions of the baseline dyspnea index
Study: 17521397
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.i.d (12 patients)
Study: 17521397
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (10 patients)
Study: 15203296
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Paroxetine (active medication)
Study: 11380322
Drug: LCM-7 (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCM-7 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg twice daily for 7 days)
Study: 11380322
Drug: LCMB-3 (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCMB-3 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, bismuth subcitrate 240 mg twice daily for 3 days)
Study: 8062489
Drug: Probenecid (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (2 gm) with adinazolam (60 mg)
Study: 8062489
Drug: Adinazolam (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam (60 mg)
Study: 2839025
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Calcium and 25 micrograms cholecalciferol per day
Study: 29310711
Drug: Collaborative pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Collaborative pharmaceutical care with medication reconciliation and review performed by a clinical pharmacist during the experimental period
Study: 29310711
Drug: Collaborative pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Collaborative pharmaceutical care
Study: 16015413
Drug: Argatroban (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (median doses: 1.5‐2.0 mcg/kg/min)
Study: 16015413
Drug: Cotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotherapy with Argatroban and Warfarin (median dose: 5 mg initially with 3.8 mg/day thereafter)
Study: 16015413
Drug: Cotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotherapy with Argatroban and Warfarin
Study: 15259476
Drug: 14-day primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day primaquine regimen (15 mg/d)
Study: 15259476
Drug: No antirelapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antirelapse therapy
Study: 10997897
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) + vaginal meteneprost (5 mg)
Study: 10997897
Drug: Mifepristone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (200 mg) + oral misoprostol (600 microg)
Study: 31309857
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (LT)
Study: 31728510
Drug: Early intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early intervention with anti-TNF-α treatment
Study: 31728510
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (steroids and/or immunomodulators)
Study: 27509063
Drug: Cetuximab (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (EGFR inhibitor)
Study: 20858862
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily) concomitantly with clopidogrel
Study: 20858862
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily) staggered by 8 to 12 hours with clopidogrel
Study: 17600281
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (Talpha1) as an adjunct to influenza vaccination
Study: 15603047
Drug: Parenteral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotics (metronidazole and cefoxitin)
Study: 9871432
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (controlled by feedback, twice daily)
Study: 9871432
Drug: Usual doses
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual doses of cyclosporine and corticosteroids
Study: 7639018
Drug: vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine + low-dose DETOX (10 micrograms MPL + 100 micrograms CWS)
Study: 7639018
Drug: vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine + high-dose DETOX (20 micrograms MPL + 200 micrograms CWS)
Study: 7639018
Drug: vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine + alum (control group)
Study: 7639018
Drug: DETOX group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DETOX group (combined low and high dose)
Study: 1695304
Drug: Isradipine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 1.25 mg b.i.d.
Study: 1695304
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 mg b.i.d.
Study: 365541
Drug: Ordinary lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary lithium carbonate (1.80 g = 24.3 mmol)
Study: 365541
Drug: Sustained-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release lithium carbonate (1.80 g = 24.3 mmol)
Study: 365541
Drug: Healthy volunteers
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers (ordinary preparation)
Study: 365541
Drug: Manic subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manic subjects (sustained-release preparation)
Study: 29062324
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (5000 IU) and Vitamin C (2600 mg) supplementation for 1 month
Study: 21628364
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin D supplements (35 µg/week) for six months
Study: 16966109
Drug: Antibiotics (clindamycin-gentamycin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (clindamycin-gentamycin)
Study: 11423708
Drug: Nitrate withdrawal
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate withdrawal (40 mg isosorbide dinitrate twice daily)
Study: 3780125
Drug: SQ 28,668
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ 28,668 (doses ranging from 25 to 1200 mg)
Study: 22425129
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity extracorporeal shock wave therapy
Study: 20110563
Drug: Single retinyl
Normalized name: RETINYL PALMITATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single retinyl palmitate dose of 200,000 IU (S1)
Study: 20110563
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of retinyl palmitate 200,000 IU 24 hours apart (S2)
Study: 12810415
Drug: Grilled spinach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grilled spinach with sour cream
Study: 19853906
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg
Study: 8350584
Drug: Prophylactic vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic vancomycin (10 mg/kg/day in two doses)
Study: 8350584
Drug: Vancomycin plus
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin plus oral cefixime for patients with positive cultures for gram-negative organisms
Study: 3001520
Drug: vidarabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: vidarabine (15 mg/kg/day for 10 days)
Study: 3001520
Drug: acyclovir (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: acyclovir (30 mg/kg/day for 10 days)
Study: 29622512
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated grafts
Study: 12639494
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of inactivated poliovirus vaccine (IPV) at 6, 10, and 14 weeks together with oral poliovirus vaccine (OPV)
Study: 12639494
Drug: One additional
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One additional dose of IPV at 14 weeks together with the last dose of OPV
Study: 8773088
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg daily for 2 weeks and then tapered off)
Study: 23995520
Drug: Sunscreen milk
Normalized name: ZINC OXIDE 12 g in 100 mL TOPICAL LOTION [GUARDIAN ANGEL SUPER PEPTIDE SUNSCREEN MILK SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen milk formulation
Study: 23995520
Drug: Sunscreen gel
Normalized name: AVOBENZONE 3 mg in 100 mg / HOMOSALATE 9.5 mg in 100 mg / OCTISALATE 5 mg in 100 mg TOPICAL LOTION [NEORA Invisibloc Sunscreen Gel Broad Spectrum SPF40]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen gel formulation
Study: 18625073
Drug: Combination botanical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination botanical product (CBP) 2 tablets three times a day
Study: 18625073
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg once a day
Study: 18625073
Drug: Combination botanical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination botanical product (CBP)
Study: 18625073
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the treatments
Study: 7573999
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (50 micrograms.kg‐1.min‐1)
Study: 7572495
Drug: Triple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple dose (0.3 mmol/kg) of gadoteridol
Study: 7572495
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (0.1 mmol/kg) of gadoteridol
Study: 30823449
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg once a day (OD)
Study: 30823449
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice a day (BID)
Study: 28162215
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia (40 mg parecoxib sodium IV before anesthetic induction, 0.375% ropivacaine 150 mg with dexamethasone 5 mg for transversus abdominis plane block)
Study: 25835348
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (Prevacid; 30 mg)
Study: 20023244
Drug: Standard dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dressing without healing promoting agent
Study: 15585901
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with ADHD on medication
Study: 15585901
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with ADHD without medication
Study: 9425640
Drug: levodropropizine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodropropizine syrup (60 mg t.i.d. for 5 days)
Study: 9425640
Drug: dextromethorphan syrup
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dextromethorphan syrup (15 mg t.i.d. for 5 days)
Study: 3318431
Drug: Nabumetone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (2 g daily)
Study: 3318431
Drug: Naproxen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1 g daily)
Study: 25743367
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (3x weekly)
Study: 23249842
Drug: Grass silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass silage supplemented with 4 kg concentrate daily
Study: 23249842
Drug: Grass silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass silage supplemented with 8 kg concentrate daily
Study: 23249842
Drug: Maize silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize silage (DM 217 g/kg) as sole forage supplemented with 4 kg concentrate daily
Study: 23249842
Drug: Maize silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize silage (DM 304 g/kg) as sole forage supplemented with 4 kg concentrate daily
Study: 23249842
Drug: Maize silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize silage (DM 217 g/kg) offered as 0.5 of the forage component of the diet supplemented with 4 kg concentrate daily
Study: 23249842
Drug: Maize silage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maize silage (DM 304 g/kg) offered as 1.0 of the forage component of the diet supplemented with 4 kg concentrate daily
Study: 20890207
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g every 6 h)
Study: 20890207
Drug: Dipyrone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (1 g every 6 h)
Study: 20890207
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg every 12 h)
Study: 12452232
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine titration in the PACU
Study: 12452232
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine on demand every 6 hours
Study: 9053973
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times a day for 7 days)
Study: 9053973
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times a day for 7 days) + Misoprostol (200 micrograms every 6 hours for 7 days)
Study: 1791771
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate plus 0.25 mg norgestrel (Cyclabil)
Study: 1791771
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate plus 7.5 mg megestrol acetate (EV + MA)
Study: 7043657
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg sulprostone four hourly with laminaria
Study: 7043657
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg sulprostone four hourly without laminaria
Study: 7043657
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg sulprostone eight hourly with laminaria
Study: 7043657
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg sulprostone eight hourly without laminaria
Study: 25989381
Drug: Silver Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Cap (medical topical treatment device)
Study: 25989381
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for nipple fissure treatment (control group)
Study: 24030410
Drug: Full prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full prescription coverage
Study: 22080794
Drug: Usual prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual prescription coverage
Study: 17014513
Drug: Surveillance swab
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surveillance swab cultures (Ssc) with topical therapy based on Ssc results (Group A)
Study: 1536666
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Auranofin and Methotrexate
Study: 31185083
Drug: Index of
Normalized name: gr pol-orc/sw ver/rye/Kent/tim 100 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index of Orthodontic Treatment Need (IOTN) - Dental Health Component (DHC)
Study: 31185083
Drug: Index of
Normalized name: gr pol-orc/sw ver/rye/Kent/tim 100 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Index of Orthodontic Treatment Need (IOTN) - Aesthetic Component (AC)
Study: 31185083
Drug: Combined Index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Index of Orthodontic Treatment Need (CIOTN)
Study: 23643112
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity exercise programme including depression awareness training for care-home staff and 45 min physiotherapist-led group exercise sessions delivered twice weekly.
Study: 20626146
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with blood-letting therapy
Study: 18975346
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 200 mg plus MTX
Study: 18975346
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg plus MTX
Study: 20155996
Drug: Hypericum perforatum
Normalized name: Hypericum perforatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum perforatum 900 mg/day